

UNITED STATE DEPARTMENT OF COMMERCE Patent and Tracemark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

| | APPLICATION NO. | PLICATION NO. FILING DATE FIRST NAMED INVENTOR | | | | ATTORNEY DOCKET NO. |
|---|-----------------|--|---------|--------|-----------------------|---------------------|
| | 09/711,240 | 11/13/00 | CONNELL | | M | ALT-5604D CO |
| ı | | | | \neg | EXAMINER DRODGE, J | |
| · | | | | , | | |
| | ONE BAXTER | | TING s | | ART UNIT | PAPER NUMBER |
| | DEERFIELD I | L 60015 | | | 1723 | 4 |
| | | | | | DATE MAILED | : 10/18/01 |

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Apptication No. 09/711,240

Applica...(s)

CONNELL ET AL

Examiner

JOSEPH DRODGE

Art Unit 1723



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on Sep 24, 2001 2a) This action is **FINAL**. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 30-41 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) Claim(s) 6) 💢 Claim(s) 30-41 7) Claim(s) ______ is/are objected to. are subject to restriction and/or election requirement. 8) L Claims Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ______ is/are objected to by the Examiner. 11) \square The proposed drawing correction filed on is: a) \square approved b) \square disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). ...trends in patent review" and ்டிவிக்கிக்குள்ளுள்ளுக்குகள்குரு isipandiasization in patent in patent and a se 14) Description of the second Attachment(s) Drodge, Joseph; Ocampo, Marianne :oT 15) Notice of References Cited (PTO-892) :Juas 19) Notice of Informal Patent Applibation (PTO-1)52) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) From: 17) Information Disclosure Statement(s) (PTO-1449) Paper Nots)

Drodge,

udəsor

Page 2

Art Unit: 1723

1. L

DETAILED ACTION

Request for Continued Examination

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 24, 2001 has been entered.

Claim Rejections - 35 U.S.C. § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.

Application/Control Number: 9

Art Unit: 1723

3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 30 35 and 37-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lichtenstein patent 4,370,983 in view of Rubalcaba patent 4,898,578 and/or Kerns et al patent 4,756,706.

Lichtenstein discloses a computer controlled medical care system that encompasses extracorporeal blood circulation and treatment systems including means for conducting dialysis treatment of the blood in which numerous parameters are monitored, displayed and controlled through the use of central processing units coupled to interactive monitoring, input, and appropriate or standard interactive and display units (see especially column 28, lines 60-65 and column 32, lines 26-67. Also disclosed with the medical care system are modules for conducting intravenous and drug infusion for patients (see column 31, lines 12-33).


Art Unit: 1723

The independent claims each differ from Lichtenstein in requiring the interactive input/outputs to comprise touch screens. However, each of Kerns et al and Rubalcaba teach such interactive units employed with blood infusion pumping systems, operable to allow touch screen entry of keypads effective to change at least one step of a medical procedure (see especially column 8, lines 35-45 of Rubalcaba and column 1, lines 41-59 of Kerns et al. At the time the present invention was made, it would have been obvious to one of ordinary skill in this art to have modified the system of Lichtenstein by substituting or supplementing the alphanumeric units with such touch screen units, as taught by Rubalcaba and/ or Kerns et al, in order to ease user confusion and error in entering data and prevent extra errors from occurring during crisis situations, as suggested by Rubalcaba and/or prevent confusion in entering data due to detachment and reattachment of components to the central processor, as suggested by Kerns et al.

Regarding dependent claim 35, all three references relied upon teach monitoring and control of a plurality of parameters which change both predictably and unpredictably with time.

Regarding claim 36, see Kerns et al in column 5, lnes 56-59.

Regarding claims 38 and 39, Lichtenstein in column 12, ilnes 15-48 extensively concerns monitoring and control of blood flow in dialysis conduit systems containing blood pumps.



Art Unit: 1723

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph W. Drodge whose telephone number is (703) 308-0403. The examiner can normally be reached on Monday-Friday from approximately 8:30 AM - 4:45 PM.

The fax phone number for this Group is (703) 872-9310 or (703)-872-9311 for (after final rejections). When filing a FAX in Tech Center 1700, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communication with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0661.

Joseph W. Drodge

Primary Examiner

Art Unit 1723

JWD October 17, 2001